Bioceltix is implementing the project entitled “The production of adipose tissue-derived allogeneic mesenchymal stem cells as compliant with the requirements of Good Manufacturing Practice – an active substance for the investigational medicinal product for advanced-therapy veterinary use, intended for clinical trials in the treatment of degenerative changes of joints and dysplasia in dogs”, co-financed by European Union funds within the framework of the Smart Growth Operational Programme 2014-2020, Measure 1.1.1. R&D projects aimed at commercialisation and marketing a particular solution are eligible for “fast track” co-financing.
THE SUBJECT OF THE PROJECT is to market an advanced-therapy medicinal product for veterinary use classified as a somatic cell therapy product offered in the form of allogeneic (one donor – many recipients) adipose tissue-derived mesenchymal stem cells, intended for use in treating degenerative joint diseases in dogs.
THE OBJECTIVE OF THE PROJECT is to market an advanced-therapy medicinal product for veterinary use classified as a somatic cell therapy product offered in the form of allogeneic (one donor – many recipients) adipose tissue-derived mesenchymal stem cells, intended for use in treating degenerative joint diseases in dogs.
THE RESULT OF THE PROJECT will be the creation of a certified facility for producing active pharmaceutical ingredients of advanced-therapy medicinal products for veterinary use based on allogeneic stem cells produced in accordance with the requirements of Good Manufacturing Practice. The cGMP-compliant facility will be used to produce the active pharmaceutical ingredient, which in tandem with state-of-the-art production equipment will enable the creation of an innovative, advanced-therapy medicinal product using a completely novel technology. The technology will provide the high level of quality and safety required for the production of the active pharmaceutical ingredients, the investigational medicinal products, and the finished medicinal products authorised for marketing.
THE PRODUCT will be based on a homogeneous population of allogeneic mesenchymal stem cells isolated from the adipose tissue of an eligible (screened) canine donor. The innovative characteristics of the product will be the quality and safety of the mesenchymal stem cells used as its active pharmaceutical ingredient.
Puls Biznesu about our plans: Bioceltix announces that it will soon debut on NewConnect – the company has recently completed the pre-IPO round. So far, the company has obtained a total of approx. PLN 20 million in financing for the development of a still innovative method of treating pets ...Article
Forbes about Polish start-ups in the coronavirus crisis: “The year 2020 was a big challenge for companies, individual sectors of the economy and probably all of us. In the coming weeks and months of 2021 it will be similar. The condition of start-ups is no exception here. it is easier and ...Article
According to the „Investors’ Zone”, an interesting year is being prepared on the stock exchange: “This year, an exceptionally large group of companies is choosing NewConnect. As many as 63 companies declared their willingness to enter the alternative market, and several more in the ...Article
Gazeta Wrocławska wrote about us: “Bioceltix is working on innovative biological medicines used in the treatment of common autoimmune and inflammatory diseases in companion animals. The company from Wrocław has something to fight for. This is indicated by the numbers on the global drug ...Article
We create at Bioceltix veterinary biological medicines, and in 2020 we announced plans for a stock exchange debut and we obtained a permit from the Main Pharmaceutical Inspector to manufacture veterinary biological drugs. Despite the pandemic, we continue our projects without downtime. You can ...Article